COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,280 Articles (22,759 medRxiv, 8,521 bioRxiv)

Most recent first Previous |  Page 1019: Articles 10181-10190  | Next

Should rapid antigen tests be government funded in Australia? An economic evaluation
Karnon, J., Afzali, H., Bonevski, B.
10.1101/2022.01.03.22268709 — Posted: 2022-01-05
Seroresponse to third doses of SARS-CoV-2 vaccine among patients receiving maintenance dialysis
Hsu, C. M., Lacson, E. K., Manley, H. J., Aweh, G. N., Miskulin, D., Johnson, D., Weiner, D. E.
10.1101/2022.01.03.21268549 — Posted: 2022-01-05
The French domestic "sanitary pass" did not solve Covid-19 vaccination inequities in France
Debarre, F., Lecoeur, E., Guimier, L., Jauffret-Roustide, M., Jannot, A.-S.
10.1101/2022.01.03.22268676 — Posted: 2022-01-05
Full title: COVID-19 disease progression according to initial symptoms. A telemedicine cohort study.
Murillo-Villanueva, K., Velazquez-Hernandez, B., Jacome-Mondragon, J. A., Cervantes-Llamas, J. J., Talavera, J. O.
10.1101/2022.01.03.22268669 — Posted: 2022-01-05
Test to release from isolation after testing positive for SARS-CoV-2
Quilty, B. J., Pulliam, J. R., Pearson, C. A.
10.1101/2022.01.04.21268372 — Posted: 2022-01-05
Bayesian Estimation of real-time Epidemic Growth Rates using Gaussian Processes: local dynamics of SARS-CoV-2 in England
Guzman Rincon, L. M., Hill, E. M., Dyson, L., Tildesley, M. J., Keeling, M. J.
10.1101/2022.01.01.21268131 — Posted: 2022-01-05
Preliminary modeling estimates of the relative transmissibility and immune escape of the Omicron SARS-CoV-2 variant of concern in South Africa
Gozzi, N., Chinazzi, M., Davis, J. T., Mu, K., Pastore y Piontti, A., Vespignani, A., Perra, N.
10.1101/2022.01.04.22268721 — Posted: 2022-01-05
Daily Lactobacillus Probiotic versus Placebo in COVID-19-Exposed Household Contacts (PROTECT-EHC): A Randomized Clinical Trial
Wischmeyer, P. E., Tang, H., Ren, Y., Bohannon, L., Ramirez, Z. E., Andermann, T. M., Messina, J. A., Sung, J. A., Jensen, D., Jung, S.-H., Artica, A., Britt, A., Bush, A., Johnson, E., Lew, M. V., Miller, H. M., Pamanes, C. E., Racioppi, A., Zhao, A. T., Surana, N. K., Sung, A. D.
10.1101/2022.01.04.21268275 — Posted: 2022-01-05
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
Eugenia-Toledo-Romani, M., Garcia-Carmenate, M., Verdecia-Sanchez, L., Perez-Rodriguez, S., Rodriguez-Gonzalez, M., Valenzuela-Silva, C., Paredes-Moreno, B., Sanchez-Ramirez, B., Gonzalez-Mugica, R., Hernandez-Garcia, T., Orosa-Vazquez, I., Diaz-Hernandez, M., Perez-Guevara, M. T., Enriquez-Puertas, J., Noa-Romero, E., Palenzuela-Diaz, A., Baro-Roman, G., Mendoza-Hernandez, I., Munoz, Y., Gomez-Maceo, Y., Santos Vega, B. L., Fernandez-Castillo, S., Climent-Ruiz, Y., Rodriguez-Noda, L. M., Santana-Mederos, D., Garcia-Vega, Y., Wu-Chen, G., Doroud, D., Biglari, A., Boggiano-Ayo, T., Valdes-Balbin, Y., Garcia-Rivera, D., Verez-Bencomo, V.
10.1101/2022.01.01.21268271 — Posted: 2022-01-05
Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series
Adamson, B. J., Sikka, R., Wyllie, A. L., Premsrirut, P. K.
10.1101/2022.01.04.22268770 — Posted: 2022-01-05 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).